Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: cerevel.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/8/2023 | $45.00 | Outperform → Market Perform | TD Cowen |
| 11/20/2023 | $25.00 | Neutral | JP Morgan |
| 9/28/2023 | $33.00 | Overweight | Piper Sandler |
| 8/3/2023 | $36.00 → $31.00 | Buy → Neutral | BofA Securities |
| 5/4/2023 | $30.00 | Equal Weight → Overweight | Wells Fargo |
| 4/10/2023 | Outperform | TD Cowen | |
| 3/17/2023 | $40.00 → $29.00 | Overweight → Neutral | JP Morgan |
| 3/16/2023 | $22.00 | Hold | Berenberg |
| 2/23/2023 | $38.00 → $30.00 | Overweight → Equal Weight | Wells Fargo |
| 11/1/2022 | $40.00 | Buy | Loop Capital |
15-12G - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
EFFECT - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
25-NSE - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
S-8 POS - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
S-8 POS - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
S-8 POS - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
POS AM - Cerevel Therapeutics Holdings, Inc. (0001805387) (Filer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
4 - Cerevel Therapeutics Holdings, Inc. (0001805387) (Issuer)
Mr. Burgess will be responsible for leading Cerevel's business development and quality teams Mr. Burgess to join Cerevel effective June 20, 2023 CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Paul Burgess as chief business development and strategic operations officer, effective June 20, 2023. "I am so pleased to welcome Paul to Cerevel as our chief business development and strategic operations officer, with his proven track record of success in the biotech and pharmaceutical industry," said Ron Renaud, president and chie
Susan Altschuller, Ph.D. brings financial management, investor relations, and business planning experience from leading pharmaceutical and biotechnology companies to Cerevel Dr. Altschuller to become CFO effective May 15, 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Susan Altschuller, Ph.D. as chief financial officer (CFO), effective May 15, 2023. "We are excited to welcome Susan to Cerevel, as she brings a breadth of experience leading biopharmaceutical companies by leveraging her strategic understanding, f
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Scott M. Akamine as chief legal officer, effective May 24, 2021. An accomplished legal executive, Mr. Akamine brings significant healthcare and biopharmaceutical experience to the role. He joins Cerevel from AEON Biopharma, Inc., a privately-held biopharmaceutical company, where he served as general counsel and corporate secretary, overseeing legal and certain administrative functions, including business development, corporate governance, intellectual property, and compliance.
TD Cowen downgraded Cerevel Therapeutics from Outperform to Market Perform and set a new price target of $45.00
JP Morgan resumed coverage of Cerevel Therapeutics with a rating of Neutral and set a new price target of $25.00
Piper Sandler initiated coverage of Cerevel Therapeutics with a rating of Overweight and set a new price target of $33.00
BofA Securities downgraded Cerevel Therapeutics from Buy to Neutral and set a new price target of $31.00 from $36.00 previously
Wells Fargo upgraded Cerevel Therapeutics from Equal Weight to Overweight and set a new price target of $30.00
TD Cowen initiated coverage of Cerevel Therapeutics with a rating of Outperform
JP Morgan downgraded Cerevel Therapeutics from Overweight to Neutral and set a new price target of $29.00 from $40.00 previously
Berenberg resumed coverage of Cerevel Therapeutics with a rating of Hold and set a new price target of $22.00
Wells Fargo downgraded Cerevel Therapeutics from Overweight to Equal Weight and set a new price target of $30.00 from $38.00 previously
Loop Capital initiated coverage of Cerevel Therapeutics with a rating of Buy and set a new price target of $40.00
- Reuters
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume CERE PUT TRADE NEUTRAL 07/19/24 $40.00 $56.0K 3 2.9K LFMD CALL SWEEP BULLISH 11/15/24 $7.50 $54.4K 2.
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without troublesome dyskinesia compared to those treated with LD and placebo (1.7 hours vs. 0.6 hours, p <0.0001). Also Read: AbbVie’s New $9B Neuroscience Space Deal Might Attract FTC Scrutiny, Ana
Monday, AbbVie Inc (NYSE:ABBV) agreed to acquire Landos Biopharma Inc (NASDAQ:LABP) for $20.42 per share, or approximately $137.5 million in the aggregate, plus one contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million. The proposed transaction is expected to close in the second calendar quarter of 2024. Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), anti-inflammatory, and facilitates epithelial repair. “With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-i
Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target from $25 to $45.
RBC Capital Markets has initiated Biohaven Ltd (NYSE:BHVN), noting optimized development across programs. The analyst highlights the company’s way of identifying promising technologies and targets and leveraging its management expertise to optimize the development path based on competitor data to become a fast follower in high-value therapeutic areas. RBC analyst says the Kv7 modulators are an exciting new mechanism in the neuro-psych space with a blockbuster potential of $3.2 billion across epilepsy and mood disorders and, like Biohaven’s approach of leveraging learnings from competitor Xenon Pharmaceuticals Inc (NASDAQ:XENE) to accelerate its development path. RBC has initiated
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl
Three new executives added to leadership team: Ron Renaud, Susan Altschuller, Paul Burgess Emraclidine EMPOWER data now expected second half 2024 Darigabat ADAPT trial in panic disorder initiated Cash, cash equivalents, and marketable securities of $825.1 million as of June 30, 2023, expected to support a data-rich 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the second quarter ended June 30, 2023 and provided key pipeline and business updat
CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2023 financial results and business updates on Wednesday, August 2, 2023, before the U.S. financial markets open. Management will host a conference call to discuss second quarter financial results and business updates on Wednesday, August 2 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be available on
Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Emraclidine Phase 2 schizophrenia data readout on track for 1H 2024 Darigabat Phase 2 epilepsy data readout expected mid-year 2024; panic disorder Phase 2 trial expected to initiate in Q2 2023 Cash, cash equivalents, and marketable securities of $863.0 million as of March 31, 2023, expected to support seven data readouts in 2024 and fund operations into 2025 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mas
CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wednesday, May 3, 2023, before the U.S. financial markets open. Management will host a conference call to discuss first quarter financial results and business updates on Wednesday, May 3 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be available on the in
CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22, 2023, before the U.S. financial markets open. Management will host a conference call to discuss fourth quarter and full year 2022 financial results and business updates on Wednesday, February 22 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with
CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open. Management will host a conference call to discuss third quarter 2022 financial results and recent business updates on Tuesday, November 8, 2022, at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.A live webcast of the call, along with supporting slides, will be available on the i
Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future development in Alzheimer's disease psychosis Panic disorder selected as second indication for darigabat, planning underway for Phase 2 proof-of-concept Cash, cash equivalents and marketable securities of $531M as of June 30, 2022, expected to support operations into 2024 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today r
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2022 financial results on Monday, August 1, 2022, before the U.S. financial markets open. Management will host a conference call to discuss second quarter 2022 financial results and recent business updates on Monday, August 1, 2022 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number.A live webcast of the call, along with supporting slides, will be available on the invest
Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's diseaseEmraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophreniaCerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decadeAbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- If you invested in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation or contacting us below. Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie. Under the terms of the transaction, AbbVie will acquire all outstanding shares of Cerevel for $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion. The boards of directors of both companies have approved the transaction. This transaction is expected to clo
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total "on" time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon's potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson's disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherapy trials (TEMPO-1 and TEMPO-2) are expected in the second half of 2024 CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unrav
Proposed acquisition adds robust pipeline of assets focused on best-in-class potential for psychiatric and neurological disorders where significant unmet needs remainCerevel's clinical-stage pipeline complements AbbVie's current on-market portfolio and emerging neuroscience pipelineEmraclidine has the potential to transform the standard of care in schizophrenia and other psychiatric conditionsTransaction valued at $45.00 per share in cash, for a total equity value of approximately $8.7 billionAbbVie to hold an investor conference call tomorrow, December 7, at 8:00 a.m. CTNORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) and Cerevel Therapeutics (N
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson's disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET CAMBRIDGE, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will host a tavapadon investor webcast on Monday, December 11, from 10:00 to 11:30 a.m. ET. Cerevel will lead an in-depth discussion of tavapadon, its D1/D5 partial agonist currently in Phase 3 development for the treatment of Parkinson's disease. The event will include remarks and insights from Hubert Fer
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that members of the management team will participate in two upcoming investor conferences during the month of November. President and chief executive officer Ron Renaud will also participate in fireside chats at both conferences. Event:Jefferies London Healthcare Conference Date:November 14, 2023Time: 9:00 a.m. GMT fireside chat Event:6th Annual Evercore ISI HealthCONx ConferenceDate:November 30, 2023Time:9:10 a.m. ET fireside chat Live webcasts of the fireside chats will be available on the in
Raised $499 million of net proceeds from public offering of common stock, expected to support operations into 2026 2024 data readout timelines for emraclidine, darigabat, and tavapadon remain on track Tavapadon investor webcast scheduled for December 11, 2023 Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics, (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today reported financial results for the third quarter ended September 30, 2023 and provided key pipeline and business updates. "Cerevel is bringing forward one of the broadest neuroscience pipelines in
CAMBRIDGE, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2023 financial results and business updates on Wednesday, November 1, 2023, before the U.S. financial markets open. Management will host a conference call to discuss third quarter financial results and business updates on Wednesday, November 1 at 8:00 a.m. ET. To access the call, please register at this link. Once registered, you will receive the dial-in information and a unique PIN number. A live webcast of the call, along with supporting slides, will be availabl
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 19,728,189 shares of its common stock at a public offering price of $22.81 per share, or approximately $450 million of shares of its common stock. In addition, Cerevel granted the underwriters a 30-day option to purchase up to an additional 2,959,228 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 16, 2023, subjec
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today that it has commenced an underwritten public offering of $400.0 million of shares of its common stock. In connection with this offering, Cerevel expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering of common stock is subject to market and other conditions and there can be no assurance as to whether or when the offering may
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13G/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D/A - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)
SC 13D - Cerevel Therapeutics Holdings, Inc. (0001805387) (Subject)